Skip to main content

Table 6 HR estimates of multivariate analyses for MDM2 SNP309 stratified by TP53 R72P

From: Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients

  HR Lower and upper limit 95% CI Pvalue HR Lower and upper limit 95% CI Pvalue HR Lower and upper limit 95% CI Pvalue
  TP53R72P: GG TP53R72P: GC TP53R72P: CC
MDM2 SNP309 TT 1.0 (Ref)     1.0 (Ref)     1.0 (Ref)    
   TG .90 .73 1.11 .33 .94 .73 1.20 .61 .85 .47 1.55 .60
   GG .85 .63 1.16 .31 1.43 1.05 1.96 .02 1.39 .56 3.48 .48
p53 negative 1.0 (Ref)     1.0 (Ref)     1.0 (Ref)    
   positive 1.37 .96 1.96 .08 .89 .58 1.35 .57 .76 .25 2.30 .63
   missing 1.63 1.16 2.28 .005 1.66 1.13 2.44 .009 .53 .21 1.34 .18
Stage 1 1.0 (Ref)     1.0 (Ref)     1.0 (Ref)    
   2 2.51 1.90 3.33 < .001 2.55 1.88 3.46 < .001 1.48 .73 2.97 .28
   3 7.10 5.05 9.97 < .001 7.56 5.18 11.02 < .001 5.49 2.17 13.87 < .001
   missing 3.69 2.42 5.63 < .001 2.55 1.54 4.21 < .001 1.60 .46 5.57 .46
Grade 1 1.0 (Ref)     1.0 (Ref)     1.0 (Ref)    
   2 1.80 1.27 2.54 .001 1.12 .77 1.62 .55 3.28 1.29 8.35 .01
   3 2.63 1.84 3.76 < .001 2.39 1.65 3.46 < .001 4.08 1.55 10.79 .005
   missing 1.84 1.21 2.78 .004 1.391 .87 2.22 .17 2.11 .64 6.92 .22
ER negative 1.0 (Ref)     1.0 (Ref)     1.0 (Ref)    
   positive .63 .48 .84 .002 .61 .44 .83 .002 .59 .27 1.26 .17
   missing .65 .46 .91 .01 .58 .40 .84 .003 .90 .36 2.25 .82
Age 1.02 1.01 1.03 .001 1.00 .99 1.02 .54 1.01 .98 1.04 .70
  1. Models have also been adjusted for study.